Clinical Trials

On The Horizon – MDV3100 in Men With Advanced Prostate Cancer Study Will Be Stopped Early and MDV3100 Offered to All Participants

It was announced yesterday that the Independent Data Monitoring Committee (IDMC) has informed the the pharmaceuticals, Medivation and Astellas of positive results from a planned interim analysis of the Phase 3 AFFIRM trial of MDV3100 in men with advanced prostate cancer previously treated with chemotherapy. The monitoring committee found that MDV3100, the first androgen receptor [...]

By |2017-10-19T10:51:56-04:00November 4th, 2011|Advanced Prostate Cancer, Chemo Therapy Failure, Clinical Trials, Clinical Trials, Drugs & Treatments, MDV3100, On The Horizon, Uncategorized|1 Comment
Read More

On The Horizon – Some More Information & An Update On MDV3100

Many of us are aware of the newly approved drug Zytiga (abiraterone). It had demonstrated a survival advantage for men who are castrate resistant and failed chemotherapy. Zytiga was approved by the FDA in April and many of us with advanced prostate cancer have been taking advantage of the drug. You can learn more about [...]

By |2017-10-19T10:51:59-04:00October 16th, 2011|abiraterone acetate, Advanced Prostate Cancer, Chemo Therapy Failure, Clinical Trials, Clinical Trials, Drugs & Treatments, MDV3100, On The Horizon, Provenge, Uncategorized, Understanding APC|2 Comments
Read More

On The Horizon- Coming Soon – Radium-223 (Alpharadin) A Bone Targeted Treatment for Advanced Prostate Cancer that Extends Life

At the recent European Multidisciplinary Cancer Congress in Stockholm, Dr Chris Parker from The Royal Marsden Hospital presented results of the phase 3 ALSYMPCA trial that showed both delayed time to first skeletal-related event (SRE) AND an overall survival (OS) benefit for those men with advanced prostate cancer taking radium-223 (Alpharadin). The real significance of [...]

By |2011-10-04T15:33:19-04:00October 4th, 2011|abiraterone acetate, Advanced Prostate Cancer, Alpharadin (radium-223), bisphosphonates, Cabazitaxel, Chemo Therapy Failure, Clinical Trials, Clinical Trials, denosumab - Xgeva, Drugs & Treatments, On The Horizon, Uncategorized, Zometa|1 Comment
Read More

A Goal Date for the Possible FDA Approval of Xgeva® (Denosumab) for men with Advanced Prostate Cancer

Amgen (NASDAQ: AMGN) today published a press release that said the U.S. Food and Drug Administration (FDA) will target an action date of April 26, 2012 for the supplemental Biologics License Application (sBLA) (approval) to expand the indication for XGEVA® (denosumab) to treat men with castrate-resistant prostate cancer with the goal of reducing the risk [...]

By |2011-08-23T09:47:50-04:00August 23rd, 2011|Advanced Prostate Cancer, Clinical Trials, Clinical Trials, denosumab - Xgeva, FDA, Uncategorized, Understanding APC|1 Comment
Read More

A Provenge Like Treatment Demonstrates Extraordinary Results Treating Leukemia – A Phase I Trial Using the Technique In Post Chemo Prostate Cancer Treatment

The most exciting news today is about some research performed at the University of Pennsylvania where researchers took blood from the three leukemia patients and isolated the T cells, a type of immune cell in the blood. T cells recognize invading organisms and kill them, however they do not recognize cancer cells as invading cells, [...]

By |2020-02-04T11:34:16-05:00August 12th, 2011|Advanced Prostate Cancer, Chemo Therapy Failure, Clinical Trials, Clinical Trials, Drugs & Treatments, On The Horizon, Uncategorized, Understanding APC, vaccines|2 Comments
Read More

Clinical Trials for Prostate Cancer: Myths & Facts

Clinical trials are important both for your treatment and for the purpose of advancing our knowledge about drugs and treatments against prostate cancer. The treatment of advanced and recurrent prostate cancer has made significant steps over the last 2 years, but without the active participation of all of us our progress will be slowed, perhaps [...]

By |2017-10-19T10:52:11-04:00August 8th, 2011|Advanced Prostate Cancer, Clinical Trials, Clinical Trials, Drugs & Treatments, Uncategorized, Understanding APC|0 Comments
Read More

Intermittent Androgen Deprivation (IAD)- No Longer Considered Experimental for Treating Men with Advanced Prostate Cancer

Changing the Standard of Care for Men with Recurrent and Advanced Prostate Cancer, Men receiving androgen deprivation therapy (ADT) for the treatment of advanced or metastatic prostate cancer know all to well the terrible side effects this treatment modality can cause. These side effects can include fatigue, hot flashes, mood swings, inability to concentrate as [...]

By |2017-10-19T10:52:15-04:00August 1st, 2011|Advanced Prostate Cancer, Clinical Trials, Clinical Trials, Drugs & Treatments, Hormone Therapy, Uncategorized, Understanding APC|2 Comments
Read More

Request for the Approval of Denosumab to Protect Bones in Men with Advanced Prostate Cancer

Amgen has submitted a supplemental Biologics License Application (sBLA) to the FDA to expand the indication for denosumab (XGEVA) its RANK ligand inhibitor to treat men with castrate-resistant prostate cancer to reduce the risk of developing bone metastases. Although some doctors have already begun to use Xgeva in men with advanced prostate cancer, it is [...]

By |2011-07-18T15:45:06-04:00July 18th, 2011|Advanced Prostate Cancer, Clinical Trials, Clinical Trials, denosumab - Xgeva, Drugs & Treatments, General Information, Uncategorized, Understanding APC|0 Comments
Read More

On the Horizon- Final Results of VENICE First-Line Hormone-Refractory Metastatic Prostate Cancer Trial Expected in 2012

Regeneron Pharmaceuticals, Inc. announced that the Phase 3 VENICE clinical trial evaluating the investigational agent Zaltrap (aflibercept) in the first-line treatment of men with castrate resistant prostate cancer will continue to completion as planned. They have not been asked to make any modifications due to efficacy or to safety concerns. This decision is based on [...]

By |2017-10-19T10:52:18-04:00July 12th, 2011|Advanced Prostate Cancer, Clinical Trials, Clinical Trials, Drugs & Treatments, Uncategorized, Zaltrap (aflibercept)|0 Comments
Read More
Go to Top